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Background: Catheter ablation has become a well-established indication for long-term
rhythm control in atrial fibrillation (AF) patients refractory to anti-arrhythmic drugs
(AADs). Efficacy and safety of AF catheter ablation (AFCA) before AADs failure are,
instead, questioned.
Objective: The aim of the study was to perform a systematic review and meta-analysis
of randomized clinical trials (RCTs) comparing first-line AFCA with AADs in symptomatic
patients with paroxysmal AF.
Methods: We performed a random-effects meta-analysis of binary outcome events
comparing AFCA with AADs in rhythm control-naïve patients. The primary outcomes,
also stratified by the type of ablation energy (radiofrequency or cryoenergy), were
(1) recurrence of atrial tachyarrhythmias and (2) recurrence of symptomatic atrial
tachyarrhythmias. The secondary outcomes included adverse events.
Results: Six RCTs were included in the analysis. AFCA was associated with lower
recurrences of atrial tachyarrhythmias [relative risk (RR) 0.58, 95% confidence interval
(CI) 0.46–0.72], consistent across the two types of ablation energy (radiofrequency,
RR 0.50, 95% CI 0.28–0.89; cryoenergy, RR 0.60, 95% CI 0.50–0.72; p-value for
subgroup differences: 0.55). Similarly, AFCA was related to less symptomatic arrhythmic
recurrences (RR 0.46, 95% CI 0.27–0.79). Overall, adverse events did not differ. A
trend toward increased periprocedural cardiac tamponade or phrenic nerve palsy was
observed in the AFCA group, while more atrial flutter episodes with 1:1 atrioventricular
conduction and syncopal events were reported in the AAD group.
Conclusions: First-line rhythm control therapy with AFCA, independent from the
adopted energy source (radiofrequency or cryoenergy), reduces long-term arrhythmic
recurrences in patients with symptomatic paroxysmal AF compared with AADs.
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INTRODUCTION
Atrial fibrillation (AF) is the most common supraventricular
arrhythmia, affecting up to 2% of the population (1). Anti-
arrhythmic drugs (AADs) are considered as the first-line option
for the maintenance of sinus rhythm (rhythm control) in
patients with symptomatic AF episodes; however, they are limited
by a relatively low efficacy and substantial side effects (2–
4). AF catheter ablation (AFCA) has established itself as a
superior alternative to AADs in terms of long-term sinus rhythm
maintenance and quality of life (5, 6). Accordingly, AFCA has
been recommended in case of AAD failure by the most recent
guidelines (1, 7).
A possible role for AFCA also as first-line option in
paroxysmal AF is emerging. A shorter time between first AF
documentation and ablation is associated with lower arrhythmic
recurrences, implying a lower probability of disease progression
toward persistent AF (4, 8, 9). In the last decade, three
randomized clinical trials (RCTs) evaluating radiofrequency
(RF) ablation compared with AADs as first-line treatment
in rhythm control-naïve patients (10–12) had demonstrated
lower recurrence rate by ablation, at the price of transiently
exposing the patient to the rare, but not negligible, risk of
periprocedural complications (13). More recently, three RCTs
comparing cryoballoon ablation and AADs as first-line rhythm
control therapy have been published (14–16).
The aim of the present study is to perform an updated
systematic review and meta-analysis comparing efficacy and
safety of AFCA vs. AADs as first-line rhythm control strategy in
patients with paroxysmal AF, also assessing potential differences
related to ablation energy source (RF or cryoenergy).
METHODS
The present systematic review and meta-analysis was performed
in accordance to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines (17).
Search Strategy, Study Selection, and
Quality Assessment
We screened PubMed/MEDLINE and Embase databases from
their inceptions to March 7, 2021, using the following search
terms: “atrial fibrillation AND ablation AND first-line.”
The inclusion criteria were as follows: (a) prospective RCTs
comparing AFCA (RF or cryoballoon ablation) with AADs
as first-line rhythm control treatment in symptomatic AF;
and (b) availability of data regarding arrhythmic recurrences
(symptomatic or asymptomatic).
Two investigators (AS and MA) independently reviewed the
titles/abstracts and studies to determine their eligibility based
on the inclusion criteria and extracted all the relevant features,
including study characteristics, baseline population data, and
outcomes (assessment and measures). A third reviewer (GMDF)
resolved disagreement. Risk of bias assessment was performed at
the study level using the Cochrane bias risk assessment tool (RoB
2) (18).
Outcomes
The primary efficacy outcomes of the present analysis were
as follows: (1) recurrence of atrial tachyarrhythmias and (2)
recurrence of symptomatic atrial tachyarrhythmias. According to
study design, recurrent atrial tachyarrhythmia included AF alone,
or AF and/or atrial tachycardia/atrial flutter (AT/AFL).
The secondary outcome endpoints were all-cause death,
proportion of crossover to the alternative arm, proportion of
patients undergoing ablation after failure of the initial treatment
(either AFCA or AADs), stroke/transient ischemic attack (TIA),
cardiac tamponade, phrenic nerve palsy, atrioesophageal fistula,
pulmonary vein (PV) stenosis >70%, atrial flutter with 1:1 AV
conduction, ventricular tachycardia, symptomatic bradycardia
requiring pacemaker implantation, and syncope.
Statistical Analysis
Baseline characteristics of pooled study populations were
reported as median values between the included studies, along
with their interquartile range (IQR). Random-effects model
meta-analysis of binary outcome events, taking into account the
estimated between-study heterogeneity, was performed for the
present analysis using inverse-variance method. The resulting
meta-analytic relative risk (RR) of observing the investigated
outcomes in AFCA group compared with AAD group, along
with their 95% confidence interval (CI), is reported. Forest plots
for the primary outcome endpoints are shown, stratified by
ablation energy type (RF or cryoenergy). A test for subgroup
differences was also performed. Heterogeneity across studies was
assessed using the Cochran Q test. Higgins I2 statistics was
used to determine the degree of between-study heterogeneity
(I2 < 25%, low; 25–50%, moderate; and >50%, high degree of
heterogeneity). Due to the low number of studies included, we
did not investigate publication bias, and we did not performed
meta-regression to assess potential source of heterogeneity. P-
values <0.05 were considered statistically significant. Statistical
analyses were performed with R version 4.0.0 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Included Studies and Population
Characteristics
A total of 342 studies were identified by literature search.
After detailed evaluation, six RCTs (10–12, 14–16) were finally
included in the systematic review and meta-analysis (refer to
Supplementary Figure 1 for PRISMA flowchart). The 5-year
follow-up data of MANTRA-PAF (19) was not considered since
clinical assessment and electrocardiographic monitoring were
not performed between the second and 5th year. The main
characteristics of the included RCTs are reported in Table 1.
Ablation energy was RF in RAAFT-1 (10), MANTRA-PAF (11),
and RAAFT-2 (12) while cryoenergy in EARLY-AF (14), STOP-
AF (15), and Cryo-FIRST (16). Further, details regarding study
inclusion/exclusion criteria and study-specific endpoints may
be found in the Supplementary Tables 1, 2. Risk of bias in the
individual studies is reported in Figure 1: the overall risk of bias
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TABLE 1 | Main characteristics of the included randomized clinical trials comparing first-line catheter ablation with antiarrhythmic drugs in symptomatic atrial fibrillation.












































2014–2018 107/111 100% Cryoenergy 12
AFCA, atrial fibrillation catheter ablation; AADs, anti-arrhythmic drugs; AF, atrial fibrillation.
FIGURE 1 | Risk of bias assessment using Cochrane risk of bias 2 (RoB 2) tool.
for five studies was low, while RAAFT-1 trial (10) was considered
at high risk of bias due to the unblinded outcome adjudication.
The resulting meta-analytic population encompassed 1,204
patients [603 randomized to AFCA (365 cryoballoon ablation,
61%; 238 RF ablation, 39%) and 601 to AADs], with a median
follow-up of 12 (IQR 12–24) months. AF type was paroxysmal
in nearly the totality of the patients (99%, IQR 96–100%).
Median age was 55 (IQR 54–59) years, with nearly 2:1 male-
to-female ratio (male 70%, IQR 68–71%). Hypertension was
the most frequent concurrent comorbid condition (37%, IQR
33–41%), while baseline heart failure was rare [2%, IQR 1–
6%; left ventricular ejection fraction (LVEF) 61%, IQR 60–
61%]. Median left atrial antero-posterior diameter was 40mm
(IQR 38–41mm). Mean CHADS2 score in MANTRA-PAF
(11) and RAAFT-2 (12) was 0.6, while mean CHA2DS2-
VASc score was 1.9 in EARLY-AF (14); 66% and 86% of the
patients in STOP-AF (15) and in Cryo-FIRST (16), respectively,
had a CHA2DS2-VASc score ≤2; and 58% (IQR 51–60%)
of the patients were on beta-blocker therapy at the time
of randomization.
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Table 2 reports study-specific ablation protocol, AAD use
in both treatment arms, type of monitoring, and definition
of arrhythmic recurrence. All patients underwent PV isolation
(PVI). In two RF studies, additional ablation lesion was also
allowed at the physician’s discretion [MANTRA-PAF (11) and
RAAFT-2 (12)], while in Cryo-FIRST study, additional freeze
applications were allowed in case of incomplete PVI isolation
or focal trigger identification (16). AAD use in AFCA arm was
only allowed during post-procedural blanking period in most
of the studies. Continuous electrocardiographic monitoring with
an implantable loop recorder was only performed in EARLY-AF
(14).
Primary Endpoints
The threshold defining an arrhythmic recurrence varied between
15 s in RAAFT-1 (10) and 60 s in MANTRA-PAF (11), with the
four remaining studies used a 30-s threshold (12, 14–16).
As illustrated in Figure 2, AFCA was associated with a
higher probability of freedom from any arrhythmic recurrence
compared with AADs (RR 0.58, 95% CI 0.46–0.72, I2 = 46%),
consistent across the two types of ablation energy used (RF, RR
0.50, 95% CI 0.28–0.89, I2 = 75%; cryoenergy, RR 0.60, 95%
CI 0.50–0.72, I2 = 0%; p-value for subgroup differences: 0.55).
Similarly, AFCA is related to higher probability of freedom from
symptomatic arrhythmic recurrence (Figure 3; RR 0.46, 95% CI
0.27–0.79, I2 = 71%), irrespective of ablation energy used (RF,
RR 0.46, 95% CI 0.22–0.98, I2 = 76%; cryoenergy, RR 0.42, 95%
CI 0.25–0.71, I2 = 0%; p-value for subgroup differences: 0.85).
Sensitivity analysis only considering studies with low risk of bias
gave similar results (Supplementary Figures 2, 3).
Secondary Endpoints
Secondary endpoints are detailed in Table 3, while forest plots
are reported in Supplementary Figures 4–14. All-cause deaths
TABLE 2 | Study-specific ablation protocol, AAD use in both treatment arms, type of monitoring, and definition of arrhythmic recurrence.
Study Ablation protocol AAD therapy AAD use after index
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AAD, antiarrhythmic drug; AFCA, atrial fibrillation catheter ablation; AF, atrial fibrillation; PVI, pulmonary vein isolation; AT/AFL, atrial tachycardia/atrial flutter.
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FIGURE 2 | Forest plot reporting the risk of recurrence of atrial tachyarrhythmias, stratified by ablation energy (radiofrequency or cryoenergy).
FIGURE 3 | Forest plot reporting the risk of recurrence of symptomatic atrial tachyarrhythmias, stratified by ablation energy (radiofrequency or cryoenergy).
did not differ between AFCA and AAD groups (0.5 vs. 0.7%, RR
0.86, 95% CI 0.28–2.67, I2 = 0%). Crossover to the alternative
arm was significantly less frequent in AFCA compared with
AAD group (7.9 vs. 28.2%; RR 0.23, 95% CI 0.10–0.51; I2 =
77%). No significant differences in terms of stroke/TIA (0.8 vs.
0.8%, RR 0.98, CI 0.33–2.95; I2 = 0%) were found. Concerning
procedural complications, there was a nons-ignificant trend
toward more cardiac tamponade/clinically significant pericardial
effusion (1.3 vs. 0.2%; RR 2.35, CI 0.62–8.93; I2 = 0%) or
phrenic nerve palsy (1.4 vs. 0.3%; RR 2.42, CI 0.40–14.63; I2
= 4%) in the AFCA group. No atrio-esophageal fistula were
observed, and only one severe PV stenosis was documented
after an RF ablation procedure. Conversely, a trend toward
more AFL episodes with 1:1 atrioventricular conduction (0 vs.
1.5%; RR 0.25, CI 0.03–2.25; I2 = 0%) and syncope (0.2 vs.
1.4%; RR 0.30, CI 0.08–1.12; I2 = 0%) was observed in the
AAD group.
DISCUSSION
The present meta-analysis indicates that, compared with AADs,
first-line therapy with AFCA reduces arrhythmic recurrences
in symptomatic patients with paroxysmal AF independently
from the adopted energy source. This result is achieved
without exposing the patients to an increase of adverse events.
In addition, crossover to the alternative treatment arm is
significantly less frequent in patients undergoing AFCA as first-
line rhythm management. AFCA, in fact, is candidate gold
standard treatment when sinus rhythm maintenance is strongly
desired in symptomatic AF patients.
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TABLE 3 | Meta-analysis results for pre-specified secondary outcomes.












All-cause death 6 1204
(603/601)






48 (7.9%) 169 (28.2%) 0.23
(0.10–0.51)
Ablation during follow-up 6 1204
(603/601)
96 (15.9%) 169 (28.2%) 0.33
(0.12–0.88)




5 (0.8%) 5 (0.8%) 0.98
(0.33–2.95)




8 (1.3%) 1 (0.2%) 2.35
(0.62–8.93)
Phrenic nerve palsy 3* 724 (365/359) 5§ (1.4%) 1§ (0.3%) 2.42
(0.40–14.63)
Atrioesophageal fistula 6 1204
(603/601)
0 (0%) 0 (0%) n.a.
Severe pulmonary vein stenosis 4 683 (342/341) 1 (0.3%) 0 (0%) 1.43
(0.23–9.01)
Atrial flutter with 1:1
atrioventricular conduction
2 413 (206/207) 0 (0%) 3 (1.5%) 0.25
(0.03–2.25)
Ventricular tachycardia 6 1204
(603/601)








1 (0.2%) 8 (1.4%) 0.30
(0.08–1.12)
AFCA, atrial fibrillation catheter ablation; AAD, anti-arrhythmic drug.
*This outcome was evaluated in the three most recent RCTs which used cryoenergy.
§ In all cases the palsy was reversible.
Periprocedural risk, mainly characterized by cerebral
ischemic events, pericardial effusion (possibly leading to
cardiac tamponade requiring urgent pericardiocentesis), and,
particularly for cryoballoon ablation, phrenic nerve palsy is of
concern. However, AFCA has dramatically improved its safety
profile in the last decade. Technological advancement, increased
experience, and shared evidence-based protocols (20), despite an
increase in patient-specific risk profile (e.g., older patients in the
“modern” cohort), have halved periprocedural complications in
post-2010 compared with pre-2010 cohorts (2.3 vs. 5%) (21).
Conversely, AADs expose patients to a long-term risk
of potential side effects, in particular pro-arrhythmic, which
are, differently from AFCA, spread over time rather than
concentrated in a specific period (22). The present analysis
reports generally low complication rates in both study groups.
However, the median 12-month follow-up may have limited
collection of AAD-related side effects, while at the same time
it likely captures all AFCA complications. Considering that
patients initially treated with AADs, due to the overall modest
efficacy of AADs in maintaining sinus rhythm (2), frequently
undergo AFCA in the following 12 months (approximately one
third), first-line AFCA may not only significantly shorten the
“diagnosis-to-ablation time” maximizing rhythm outcome but
also potentially prevent the sum of AFCA-related periprocedural
risk and AADs side effects in drug-refractory patients.
Of note, the meta-analytic population was mainly constituted
by relatively young, symptomatic patients, without overt
underlying structural heart disease (guaranteed by the strict
RCT inclusion criteria). As an example, median age in the
CABANA (Catheter Ablation vs. Antiarrhythmic Drug Therapy
on Mortality, Stroke, Bleeding, and Cardiac Arrest Among
Patients With Atrial Fibrillation) trial (6) was significantly higher
compared with the present population (67.5 vs. 55 years),
with seven times more patients presenting with heart failure
(15 vs. 2%) and higher thromboembolic risk (82% of patients
with CHA2DS2-VASc score ≥2). Similarly, real-world data (23)
indicate that on average AFCA candidates are older, with more
comorbid conditions, higher thromboembolic risk profile, and
frequent history of treatment failure with AADs. This suggests
that particular caution should be used before extrapolating these
data to the general AF population; however, it can be speculated
that the observed low event rate of side effects in the AAD group
might also relate to the healthier population. Unlike AFCA-
related adverse events, which are mainly operator- and center-
dependent, potential toxicity of AADs is known to increase
with patient-related factors such as heart failure and underlying
structural heart disease (22).
Finally, the present is the first analysis showing that
cryoballoon ablation, previously demonstrating non-inferiority
to RF ablation for the treatment of patients with drug-refractory
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paroxysmal AF (24), has similar efficacy to RF ablation also as
a first-line option. In fact, cryoballoon ablation was reported
to have fewer cardiac tamponades than ablation, and the most
frequent and specific cryoballoon complication, phrenic nerve
palsy, resolved within 1 month in three EARLY-AF (14) patients
and was not present at 12-month follow-up in all STOP-AF cases
(15); in Cryo-FIRST, the only transient case of phrenic nerve
palsy occurred in a patient who crossed to AFCA arm after being
randomized to AAD treatment arm (16).
Limitations
Some limitations of the present analysis need to be addressed.
First, the threshold defining an arrhythmic event varied
between the included studies (from 15 to 60 s) and arrhythmia
monitoring during follow-up was heterogeneous, ranging from
clinical follow-up visits with intermittent rhythm monitoring to
continuous monitoring with implantable loop records in one
study (14). These differences may have an influence on the
observed recurrent rate, even if a change in the proportional
efficacy of the two treatment arms considered is unlikely.
Second, also the type of arrhythmia considered as arrhythmic
recurrences was variable between the studies, with two studies
only including AF and four studies considering both AF and
AT/AFL (Table 2), Nevertheless, arrhythmic recurrences are
mainly AF episodes (25); thus, it is unlikely that the present
results would have been affected by the inclusion of AT/AFL as
arrhythmic recurrences in RAAFT-1 (10) and MANTRA-PAF
(11). Third, we cannot exclude that the unblinded nature of
the studies may have contributed to ablation benefit concerning
symptomatic recurrences. Fourth, the analysis was not powered
to detect potential significant differences inmost of the secondary
outcomes. Due to the low absolute number of events, we did not
perform subgroup meta-analysis (RF or cryoenergy ablation) for
the secondary outcomes.
CONCLUSIONS
Compared with AADs, first-line therapy with AFCA,
independently from the adopted energy source (RF or
cryoenergy), reduces arrhythmic recurrences in symptomatic,
paroxysmal AF patients without increasing exposure to
complications. First-line AFCA, performed in high-volume
experienced centers with low complication rate, candidates
as for the preferable choice for sinus rhythm maintenance
in relatively young, healthy patients without overt structural
heart disease.
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